Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Uehara, Toshiki ^a   Kato, Kimitoshi ^a   Ohkusa, Toshifumi ^a   Sugitani, Masahiko ^a   Ishii, Yukimoto ^b   Nemoto, Norimichi ^a   Moriyama, Mitsuhiko ^a  

^a NIHON UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotic combination therapy; Steroids; Ulcerative colitis

Indexed keywords

AMOXICILLIN; METRONIDAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; STEROID;

ADULT; ANOREXIA; CLINICAL ARTICLE; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG FEVER; FATIGUE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; TASTE DISORDER; ULCERATIVE COLITIS; URTICARIA; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; DRUG COMBINATION; DRUG EFFECTS; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; REMISSION; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STEROIDS; TETRACYCLINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951526138     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06231.x     Document Type: Conference Paper

References (34)

1. Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel disease: why, how, and when. Curr. Opin. Gastroenterol. 2003 19 : 358 365.
2. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. In : Kirsner JB, ed. Inflammatory Bowel Disease, 5th edn.
3. Onderdonk AB, Bronson R, Cisneros R. Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect. Immun. 1987 55 : 835 836. (Pubitemid 17021986)
4. Ohkusa T, Okayasu I, Ogihara T et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003 52 : 79 83. (Pubitemid 36020770)
5. Poxton IR, Brown R, Sawyer A et al. Mucosa-associated bacterial flora of the human colon. J. Med. Microbiol. 1997 46 : 85 91. (Pubitemid 27019753)
6. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 1994 35 : 658 664.
7. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993 342 : 412 417.
8. Ohkusa T, Sato N, Ogihara T et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J. Gastroenterol. Hepatol. 2002 17 : 849 853.
9. Ohkusa T, Nomura T, Terai T et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand. J. Gastroenterol. 2005 40 : 1334 1342. (Pubitemid 41658733)
10. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994 330 : 1841 1845. (Pubitemid 24188135)
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N. Engl. J. Med. 1987 317 : 1625 1629.
12. Osada T, Ohkusa T, Okayasu T et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J. Gastroenterol. Hepatol. 2008 23 : 849 853.
13. Osada T, Ohkusa T, Yokoyama T et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: Inter- and Intra-observer consistency. Inflamm. Bowel. Dis. 2010 16 : 192 197.
14. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q. J. Med. 1961 120 : 393 407.
15. Sandborn WJ, Tremaine WJ, Schroeder KW et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994 106 : 1429 1435.
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br. Med. J. 1955 1041 1048.
17. Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Invest. 1996 98 : 945 953.
18. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 1998 161 : 5733 5744.
19. Sadlack B, Merz H, Schorle H et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993 75 : 253 261. (Pubitemid 23320289)
20. Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric flora are necessary for development of spontaneous colitis and immune system activation in IL-10- deficient mice. Infect. Immun. 1998 66 : 5224 5231. (Pubitemid 29044613)
21. Kang SS, Bloom SM, Norian LA et al. An antibiotic-responsive mouse model of fulminant ulcerative colitis. PloS Med. 2008 5 : e41.
22. Garrett WS, Lord GM, Punit S et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007 131 : 15 7. (Pubitemid 47505255)
23. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974 1 : 1067 1070.
24. Dickinson RJ, O'Connor HJ, Pinder I et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985 26 : 1380 1384. (Pubitemid 16134465)
25. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986 27 : 1210 1212.
26. Burke DA, Axon AT, Clayden SA et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 1990 4 : 123 129. (Pubitemid 20300400)
27. Lobo AJ, Burke DA, Sobala GM et al. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment. Pharmacol. Ther. 1993 7 : 155 158.
28. Mantzaris GJ, Hatzis A, Kontogiannis P et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am. J. Gastroenterol. 1994 89 : 43 6. (Pubitemid 24020050)
29. Mantzaris GJ, Archavlis E, Christoforidis P et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am. J. Gastroenterol. 1997 92 : 454 456. (Pubitemid 27108180)
30. Turunen UM, Farkkila MA, Hakala K et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998 115 : 1072 1078. (Pubitemid 28485596)
31. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. 1999 44 : 1220 1221. (Pubitemid 29297232)
32. Nomura T, Ohkusa T, Okayasu I et al. Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment. Pharmacol. Ther. 2005 21 : 1017 1027. (Pubitemid 40529736)
33. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand. J. Gastroenterol. 1995 30 : 401 407.
34. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther. 2004 20 : 1071 1082. (Pubitemid 39657940)